Early re-colonization with pseudomonas aeruginosa (PA) after treatment: a possible risk factor for development of chronic infection in cystic fibrosis (CF) patients

C. Hansen, T. Pressler, K. Nielsen, N. Høiby (Copenhagen, Denmark)

Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools
Session: Cystic fibrosis: new mechanisms, monitoring and treatment tools
Session type: E-Communication Session
Number: 2867
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Hansen, T. Pressler, K. Nielsen, N. Høiby (Copenhagen, Denmark). Early re-colonization with pseudomonas aeruginosa (PA) after treatment: a possible risk factor for development of chronic infection in cystic fibrosis (CF) patients. Eur Respir J 2008; 32: Suppl. 52, 2867

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Early eradication of pseudomonas aeruginosa (PA) in cystic fibrosis patients (CF): Which is the best treatment?
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013


Long-term evaluation of the response to aggressive treatment at the first colonization of P.aeruginosa in cystic fibrosis (CF)
Source: Eur Respir J 2001; 18: Suppl. 33, 126s
Year: 2001

Effect of prior year pulmonary exacerbation (PE) frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa (PA)
Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Year: 2018


Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections
Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Year: 2018


Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline
Source: International Congress 2017 – Update on community acquired pneumonia
Year: 2017



The efficacy of early eradication therapy in prevention of chronic pseudomonas aeruginosa infection in cystic fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 486s
Year: 2006

The impact of colonization with therapy-resistant pathogens on the survival rate after lung transplantation (LUTX) in cystic fibrosis (CF)
Source: Virtual Congress 2021 – Optimising outcomes of lung transplantation: how to move forward?
Year: 2021



Pseudomonas aeruginosa in patients with cystic fibrosis - a comparison of early eradication and conventional therapy
Source: Eur Respir J 2004; 24: Suppl. 48, 385s
Year: 2004

Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre
Source: Eur Respir J 2006; 27: 937-943
Year: 2006



Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections
Source: Eur Respir J 2012; 40: 227-238
Year: 2012



Achromobacter (A.) xylosoxidans in cystic fibrosis: prevalence and clinical relevance
Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle
Year: 2005


Lung function, symptoms and inflammatory biomarkers in patients with bronchiectasis (brx) with and without chronic pseudomonas aeruginosa (psa) colonisation
Source: Annual Congress 2009 - Translational research/biomarkers
Year: 2009


Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis},
Source: Eur Respir J 2012; 40: 1014-1023
Year: 2012



LATE-BREAKING ABSTRACT: Pseudomonas aeruginosa strain prevalence, adaptation and diversification, during chronic lung infections of UK non-cystic fibrosis bronchiectasis patients
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016

Cystic fibrosis infection with clonal strains of Pseudomonas aeruginosa: current knowledge and future management
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=105
Year: 2006

A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013


Cystic fibrosis a contagious disease. Need for segregation
Source: Annual Congress 2005 - Paediatric year in review
Year: 2005

The diagnostic value of pseudomonas aeruginosa serology as markers of early respiratory infection in young children with cystic fibrosis
Source: Annual Congress 2007 - Cystic fibrosis lung disease: from diagnosis to end-stage
Year: 2007



Emerging pathogens in cystic fibrosis
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66
Year: 2006

DNA fingerprinting of pseudomonas aeruginosa in cystic fibrosis patients: risk assessment of cross-infection in a CF centre
Source: Eur Respir J 2002; 20: Suppl. 38, 208s
Year: 2002